Apyx Medical Corp: Form 10-Q for the period ended Mar 31, 2017
Filed with the SEC on May 15, 2017 and accepted by EDGAR at May 15, 2017, 17:05 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2017-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2017-01-01 to 2017-03-31 | $8.4m | us-gaap:SalesRevenueNet |
| Cost of revenue | 3 months2017-01-01 to 2017-03-31 | $4.2m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2017-01-01 to 2017-03-31 | $4.2m | us-gaap:GrossProfit |
| Research and development | 3 months2017-01-01 to 2017-03-31 | $709.0k | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2017-01-01 to 2017-03-31 | $2.4m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2017-01-01 to 2017-03-31 | −$1.7m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2017-01-01 to 2017-03-31 | $5.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2017-01-01 to 2017-03-31 | −$1.7m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2017-01-01 to 2017-03-31 | −$0.06 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2017-01-01 to 2017-03-31 | −$0.05 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2017-01-01 to 2017-03-31 | 30,887,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2017-01-01 to 2017-03-31 | −$2.8m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2017-01-01 to 2017-03-31 | $71.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2017-03-31 | $11.5m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2017-03-31 | $24.6m | us-gaap:AssetsCurrent |
| Total assets | At period end2017-03-31 | $33.1m | us-gaap:Assets |
| Current liabilities | At period end2017-03-31 | $4.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2017-03-31 | $8.4m | us-gaap:Liabilities |
| Long-term debt | At period end2017-03-31 | $2.6m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2017-03-31 | $239.0k | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2017-03-31 | $24.7m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000719135-17-000016. Last ingested by Listed: Nov 5, 2026, 13:09 ET. Listed shows no prices and gives no investment advice.